Neural mechanisms in asthma

Clinical and Experimental Allergy, Supplement

Volumn 30, Issue 1, 2000, Pages 60-65

  Joos, G F ^a   Germonpre P R ^a   Pauwels, R A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asthma; Cholinergic; NANC; Neural mechanisms; Neurokinin receptor antagonists; Nitric oxide; Substance P; Tachykinins

Indexed keywords

NITRIC OXIDE; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST;

ASTHMA; BRONCHOSPASM; CHOLINERGIC TRANSMISSION; CONFERENCE PAPER; EXTRAVASATION; HUMAN; IMMUNOREACTIVITY; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; MUCUS SECRETION; NEUROTRANSMITTER RELEASE; NONADRENERGIC NONCHOLINERGIC NERVE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STIMULUS RESPONSE;

ASTHMA; BRONCHODILATOR AGENTS; HUMANS; PARASYMPATHETIC NERVOUS SYSTEM; RESPIRATORY SYSTEM; TACHYKININS;

EID: 0034079927     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Barnes PJ. Overview of neural mechanisms in asthma. Pulmon Pharmacol 1995; 8:151-9.
2. Bai TR. Abnormalities in airway smooth muscle in fatal asthma. Am Rev Respir Dis 1990; 141:552-7.
3. Michoud MC, Jeanneret-Grosjean A, Couture J, Amyot R. Reflex decrease of histamine-induced bronchoconstriction after laryngeal stimulation in humans. Am Rev Respir Dis 1988; 136:518-22.
4. Lammers JWJ, Barnes PJ, Chung KF. Nonadrenergic noncholinergic airway inhibitory nerves. Eur Respir J 1992; 5:239-46.
5. Ollerenshaw SL, Jarvis D, Woolcock A, Sullivan C, Scheibner T. Absence of immunoreactive vasoactive intestinal polypeptide in tissue from the lungs of patients with asthma. N Engl J Med 1989; 320:1244-8.
6. Lilly CM, Bai TR, Shore SA, Hall AE, Drazen JM. Neuropeptide content of lungs from asthmatic and nonasthmatic patients. Am J Respir Crit Care Med 1995; 157:548-553.
7. Lucchini RE, Facchini F, Turato G et al. Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am J Respir Crit Care Med 1997; 156:1963-8.
8. Tomaki M, Ichinose M, Miura M et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med 1995; 151:613-7.
9. Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, Kunkel G. Substance P and beta-endorphin-like immunoreactivity in lavage fluid of subjects with and without allergic asthma. J Allergy Clin Immunol 1992; 90:646-52.
10. Hazbun ME, Hamilton R, Holian A, Eschenbacher WC. Ozone-induced increase in substance P and 8-epi-prostaglandin F2 alpha in the airways of human subjects. Am J Respir Cell Mol Biol 1993; 9:568-72.
11. Killingsworth CR, Shore SA, Alessandrini F, Day RD, Paulauskis JD. Rat alveolar macrophages express preprotachykinin gene-I mRNA-encoding tachykinins. Am J Physiol 1997; 273:L1073-K1081.
12. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD. Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997; 159:5654-60.
13. Germonpré PR, Bullock GR, Lambrecht BN et al. Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells. Eur Respir J 1999; 14:776-82.
14. Lambrecht BN, Germonpré PR, Everaert E et al. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. Eur J Immunol 1999; 29:3815-25.
15. Germonpré PE, Joos GF, Pauwels RA. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro. Br J Pharmacol 1998; 123:1571-8.
16. Advenier C, Joos G, Molimard M, Lagente V, Pauwels R. Role of tachykinins as contractile agonists of human airways in asthma. Clin Exp Allergy 1999; 29:579-84.
17. Ichinose M, Nakajima N, Takahashi T, Yamauchi H, Inoue H, Takishima T. Protection against bradykinin-induced broncho-constriction in asthmatic patients by neurokinin receptor antagonist. Lancet 1992; 34:1248-51.
18. Joos GF, Van Schoor J, Kips JC, Pauwels RA. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics. Am J Respir Crit Care Med 1996; 153:1781-4.
19. Lunde H, Hedner J, Svedmyr N. Lack of 4 weeks treatment with the neurokinin receptor antagonist FK224, in mild to moderate asthma. Eur Respir J 1984; 7 (Suppl. 18):151s.
20. Fahy JV, Wong HH, Geppetti P et al. Effect of an NK1 receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am J Respir Crit Care Med 1995; 152:879-84.
21. Ichinose M, Miura M, Yamauchi H et al. A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 1996; 153:936-41.
22. Van Schoor J, Joos GF, Chasson BL, Brouard RJ, Pauwels RA. The effect of the NK2 tachykinin receptor antagonist, SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur Respir J 1998; 12:17-23.